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m icroRNA-122 (miR-122) was one
of the first examples of a tissue-specific
miRNA. It is highly expressed in liver,
where it constitutes 70% of the total
miRNA pool. miR-122 expression is
specific to the vertebrate lineage, where
the sequence of the mature miRNA is
completely conserved. miR-122 is a target
for extensive study due to its association
with cholesterol metabolism and hepato-
cellular carcinoma, and its important role
in promoting hepatitis C virus (HCV)
replication. This review will discuss the
biogenesis and function of miR-122.
Identification of miR-122
MicroRNAs (miRNAs) are 21–23 nuc-
leotide (nt) non-coding RNA molecules
that post-transcriptionally repress gene
expression; in animals, this is mediated
by interaction with partially comple-
mentary target sites in the 3' untranslated
region (UTR) of target mRNAs.
1 It
became apparent that these RNA mole-
cules are present in diverse eukaryotic
systems when a number of different
miRNA sequences were identified by
cloning in HeLa cells, Drosophila and
C.elegans.
2-4 miR-122 was first identified
in a subsequent study in which the cloning
approach was applied to various mouse
tissue samples. This uncovered a high
level of tissue-specific miRNA expression
and identified a number of novel miRNAs
that are only detectable in certain tissues,
including miR-122. miR-122 is highly
enriched in the liver but absent from
other tissues.
5 Moreover, miR-122 domi-
nates the miRNA content of the liver,
representing 72% of cloned sequences.
This was confirmed by RNase protec-
tion analysis indicating that miR-122 is
present at approximately 66,000 copies
per cell in adult liver, making it one
of the most highly expressed miRNAs
in any tissue.
6 miR-122 expression is
developmentally regulated, increasing in
the liver over the course of embryonic
development.
6
Conservation and Genomic
Location
An early analysis of miR-122 demon-
strated that it is conserved in 12 different
species, including human, frog and zebra-
fish.
6 As of September 2011, miR-122
expression has been detected in 18 species,
all of which are vertebrates (miRBase 17
7).
Many miRNAs are members of families
with closely related sequences and possibly
some common targets. As the main
determinant of miRNA target binding is
complementarity to the seed (nt2–8), and
to a lesser extent to nt13–16, miRNA
sequence divergence outside these regions
is common among paralogues.
8,9 The
sequence of mature miR-122 is completely
conserved between all species in which it
has been detected, and no paralogues have
been identified, suggesting that the entire
sequence is important for function
(miRBase17
7). In situ hybridization in
zebrafish indicated that the highly liver-
specific expression pattern of miR-122 is
conserved across different species.
10 No
miR-122 orthologs have been detected
in Drosophila or C.elegans, implying
that miR-122 evolved with the vertebrate
lineage, possibly in parallel with the
emergence of the liver.
RNA FAMILIES
RNA Biology 9:2, 1–6; February 2012; G 2012 Landes Bioscience
www.landesbioscience.com RNA Biology 1© 2012 Landes Bioscience.
Do not distribute.
miR-122 derives from a single genomic
locus on chromosome 18in humans.
miRNAs are generally transcribed by
RNA polymerase II (polII) as long nuclear
transcripts known as pri-miRNAs, which
undergo cleavage by Drosha to yield a
~70nt pre-miRNA hairpin, nuclear export
via Exportin5, and cytoplasmic cleavage
by Dicer to generate the mature miRNA.
9
miRNA hairpins may be located in introns
of protein-coding mRNAs, or in exons or
introns of noncoding RNAs, and many are
in clusters with other miRNA hairpins,
which are subject to common transcrip-
tional regulation.
11,12 The human miR-
122 locus is in a noncoding RNA exon
and is not part of a cluster.
11 The pri-miR-
122 gene had previously been identified as
a non-coding RNA known as hcr,
6 and
was recently characterized in detail.
13
Identification of the transcription start site
and 3' end indicated that pri-miR-122
is initially synthesized as a 7.5kb trans-
cript that is spliced to yield the 4.5kb
Figure1. (A) The structure and transcriptional regulation of the human pri-miR-122 gene. The locations of the two exons, the pre-miR-122 sequence,
and promoter elements are shown relative to the transcriptional start site as determined by.
13 HNF-4a has been experimentally shown to activate
pri-miR-122 transcription via the indicated binding site.
13 Transcriptional repression during the circadian rhythm is driven by REV-ERBa
14. This repression
is predicted to occur via the two ROREs shown in the promoter,
14 one of which overlaps with the HNF-4a binding site. (B) The pre-miR-122 sequence
is highly conserved between different species. The 23nt form of mature miR-122 is shaded. (C) Relative levels of different miR-122 isoforms identified
by deep sequencing of mouse liver.
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pri-miR-122
13 (Fig.1A). The pri-miR-
122 sequence shows only short regions of
evolutionary conservation, of which the
pre-miR-122 hairpin is the strongest
(Fig.1B). The promoter region was iso-
lated, and showed liver-specific activity
when tested in a reporter vector.
13 The
core promoter is highly conserved and
possesses elements typical of a pol II pro-
moter. It contains a conserved target site
for the liver-enriched transcription factor
hepatocyte nuclear factor 4a (HNF-4a),
which stimulates miR-122 expression.
13
Regulated Trancription and
Post-Transcriptional Modification
pri-miR-122 transcription is regulated in a
circadian fashion in mice.
14 Many hepatic
functions are subject to circadian regula-
tion, and analysis of liver miRNA expres-
sion during the murine circadian cycle
demonstrated a rhythmic change in levels
of pri- and pre-miR-122.
14 Transcriptional
repression of pri-miR-122 during the
circadian cycle is driven by the orphan
nuclear receptor REV-ERBa. Despite the
clear circadian effects on pri-miR-122
transcription, the level of mature miR-
122 does not change significantly, prob-
ably because of its high stability.
14
However, circadian regulation of pri-
miR-122 transcription does have func-
tional consequences. Microarray analysis
showed that mRNAs regulated by miR-
122 were highly enriched for transcripts
subject to circadian regulation, and the
miR-122-dependent regulation of several
important circadian mRNAs, including
the Peroxisome proliferator-activated recep-
tor β/d (Pparβ/d), was confirmed.
14 This
alteration in miR-122 target regulation in
the absence of any change in mature miR-
122 levels is not yet understood. It raises
the intriguing possibility that newly syn-
thesized miR-122 functions differently to
the pre-existing pool.
Next-generation sequencing has revealed
that post-transcriptional modification of
miRNAs, usually by the addition of one or
two 3' nucleotides, is a frequent event.
15 In
most cases the functional consequences, if
any, of such modification are unclear, but
for miR-122 3' adenylation is important
in regulating miRNA stability. Mass spec-
trometry and deep sequencing identified
several different isoforms of miR-122
in mouse liver (Fig.1C), including a
variant with a single 3' adenosine added
by the non-canonical poly(A) polymerase
GLD-2
16. In GLD-2 2/2 mice, the total
level of miR-122 decreases and the pro-
portion of the 21nt isoform that is likely to
be a precursor to degradation increases,
suggesting that 3' adenylation stabilizes
miR-122. The decrease in miR-122 levels
was accompanied by an increase in the
mRNA level of several known miR-122
targets.
16 The degradation pathway of
mammalian miRNAs is not yet established,
but this role for 3' adenylation in main-
taining miRNA stability provides an intri-
guing insight into this process. GLD-2 was
recently shown to adenylate many other
miRNAs and to reduce the effectiveness of
targeting without significantly affecting
stability,
15 raising the possibility that
adenylation has different effects on differ-
ent miRNAs. Further research will be
necessary to resolve these discrepancies.
A biological role for GLD-2 modifica-
tion of miR-122 was observed in mouse
embryonic fibroblasts, where stimulation
of p53 polyadenylation/translation by
the cytoplasmic polyadenylation element
binding protein (CPEB) drives cellular
senescence. miR-122 downregulates CPEB
expression via two 3'UTR binding sites,
and GLD-2 depletion stimulates CPEB
and p53 expression by reducing the level
of miR-122.
17 The role for miR-122 in a
non-liver cell line is interesting; it will be
important to quantify miR-122 in these
cells and to determine whether very low
level miR-122 expression in tissues other
than liver is sufficient for productive inter-
action with some targets. An unexplored
possibility is that GLD-2 modification of
other miRNAs that target p53 may be
partially responsible for the observed
effects.
Endogenous Targets and
Physiological Functions
of miR-122
The first miR-122 target to be identified
was the Cationic amino acid transporter 1
(CAT-1), which provides an important
example of regulated miRNA repression.
In fed cells, miR-122 binds to several
sites in the CAT-1 3'UTR and mediates
translational repression, accompanied by a
shift of the repressed mRNA to P bodies.
18
However, under conditions of amino acid
starvation and other cell stresses, the RNA-
binding protein HuR moves from the
nucleus to the cytoplasm and interacts
with the CAT-1 3'UTR adjacent to the
miR-122 binding sites. This results in
relief of miR-122 repression, release of
the mRNA from P bodies and recruitment
to polysomes.
18 Although there are a few
other examples of RNA binding proteins
positively or negatively regulating miRNA
activity by interaction with target 3'UTRs,
this is currently the only example of
regulated miR-122 repression. The possibi-
lity that such regulation is more widespread
remains.
Several studies have used microarray
technology following antisense-oligo-
nucleotide-mediated inhibition of miR-
122 in mouse liver to identify its
targets.
19-21 Target mRNAs such as
AldolaseA (AldoA) and N-myc downstream
regulated gene3 (Ndrg3) were consistently
identified in the different experiments,
and confirmed using reporter assays. The
overall effect of miR-122 sequestration in
the liver of mice and primates is to reduce
the level of plasma cholesterol, without
inducing detectable liver toxicity.
19-22 The
pathways by which direct miR-122 targets
regulate cholesterol metabolism have
not been fully delineated, although it
appears that indirect regulation of choles-
terol biosynthesis genes may be impor-
tant.
19,20 miR-122 also regulates systemic
iron homeostasis by repressing the target
mRNAs hemochromatosis (Hfe) and hemo-
juvelin (Hjv). These mRNAs encode
activators of the hormone hepcidin,
which regulates iron availability, and mice
with reduced miR-122 levels suffer iron
deficiency.
23
Many miRNAs have been implicated
in various cancers either as oncogenes or
tumor suppressor genes. miR-122 levels
are frequently reduced in hepatocellular
carcinoma (HCC) compared with normal
liver,
24 and lower miR-122 expression
correlates with poor prognosis.
25 Over-
expression of miR-122 reduces tumor-
igenic properties of HCC cell lines,
indicating that it functions as a tumor
suppressor.
26 miR-122 overexpression also
sensitizes HCC cells to chemotherapeutic
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agents such as sorafenib and doxirubi-
cin.
26,27 Several miR-122 targets have been
implicated in tumorigenesis, including
ADAM10, Igf1R, SRF, cyclin G1 and
ADAM17.
26-28 The factors governing
reduced miR-122 expression in HCC have
not been fully elucidated, but miR-122
levels in tumors correlate with those of
several liver-specific transcription factors,
including HNF-4a, suggesting a regula-
tory role for these proteins.
25
miR-122 and HCV
A particularly intriguing function for
miR-122 is its role in the hepatitis C virus
(HCV) replication cycle. HCV is a
positive-sense single-stranded RNA virus
with a 9.6kb genome that establishes
persistent infections in the liver, eventually
leading to cirrhosis and carcinoma.
29 miR-
122 is required for HCV replication in the
cultured human hepatic cell line Huh7,
and mediates this regulation by a direct
interaction between with two adjacent
binding sites in the 5'UTR of HCV
RNA.
30,31 Although the initial experiments
were conducted using genotype 1a and 1b
HCV RNA, the two miR-122 binding
sites are highly conserved across all HCV
genotypes. A requirement for miR-122 has
also been observed in the life cycle of
the genotype 2a JFH-1 strain, which
establishes productive infections in Huh7
cells.
32 Such positive regulation via 5'UTR
sites is a very different process to the usual
function of miRNAs in repressing gene
expression via 3'UTRs, and suggests that
miRNA function is potentially much more
varied than is currently known.
The mechanism by which miR-122
regulates HCV has proved difficult to
establish. HCV replication proceeds first
through translation of the viral polyprotein
from the genomic RNA, mediated by
an internal ribosome entry site (IRES)
immediately downstream of the miR-122
binding sites. The viral proteins then
mediate replication of the viral RNA
via a negative strand intermediate in
membrane-bound replication complexes.
33
miR-122 stimulates translation via the
HCV IRES to some extent,
34,35 but this
is not sufficient to explain its full effect on
viral replication.
36 A later stage of the viral
replication cycle must therefore also
be regulated, but this has proved difficult
to identify. HCV RNA synthesis in
either Huh7 cells or isolated replication
complexes is insensitive to miR-122.
37,38 It
remains possible that the miRNA is
involved in degradation of HCV RNA,
in its localization to functional replication
complexes, or in the translation to replica-
tion switch. miR-122 makes an unusual
interaction with HCV RNA in which the
miRNA 3' end overlaps the viral RNA 5'
end, potentially protecting it from 5' to 3'
exonuclease activity or cytoplasmic sensors
of viral RNA.
39
miR-122 regulation of HCV was
shown to require the Argonaute proteins,
40
although a different study indicated that
this requirement could be overcome by
overexpression of miR-122.
39 The ques-
tion of whether miR-122 regulates HCV
in association with a normal miRNA-
induced silencing complex (miRISC), or
requires unusual components or accessory
proteins, remains to be fully addressed.
Examination of miR-122 activation of
translation via the HCV 5'UTR suggests
that the RNA requirements for this
process are highly specialized,
35 implying
that similar mechanisms are unlikely to
be used by other miRNAs and viruses,
although this possibility has not yet been
fully explored.
There is an urgent need for new
therapies against HCV due to problems
with ineffectiveness and poor tolerance
of the existing regime of pegylated inter-
feron-a plus ribavirin.
29 As a conserved
host factor that can be effectively inhibited
without associated toxicity, and would not
be expected to evolve resistance mutations,
miR-122 presents a highly appealing
antiviral target. Santaris Pharma has
developed a locked nucleic acid (LNA)-
based antisense oligonucleotide that is
delivered to the liver and effectively
inhibits miR-122 when injected intrave-
nously. A pilot study in four chimpanzees
chronically infected with HCV showed a
substantial reduction in viral titer in the
two animals given a higher dose of the
inhibitor, and in one of the low dose
animals.
41 The reduced viral load was
maintained over several weeks of therapy
and was not accompanied by any acquisi-
tion of viral escape mutations or liver
toxicity.
41
These results are very encouraging, but
the small scale of the study and differences
in the course of HCV infection between
chimpanzees and humans mean that
clinical trials in human patients may yield
different results. A survey of miR-122
expression in HCV-infected patients did
not show any positive correlation between
miR-122 and HCV RNA levels, suggest-
ing that this interaction may not be as
straightforward in humans as it is in cell
culture.
42 However, the very high expres-
sion of miR-122 in the liver makes it
possible that even the lowest observed
miR-122 expression is sufficient to sup-
port viral replication and that knockdown
of the miRNA would be an effective
antiviral. There is currently no data on
the HCV RNA:miR-122 ratio in indivi-
dual infected hepatocytes, which would be
useful, although technically difficult, to
determine. One important consideration
when targeting miR-122 as an HCV
therapeutic is the association between
low levels of the miRNA and HCC,
although this might not be a problem if
the miR-122 inhibitor was only applied
over a short time period. Despite these
caveats, inhibition of miR-122 holds
enormous promise as an antiviral therapy.
Excitingly, the Santaris Pharma inhibitor,
known as miravirsen, is currently in phase
II clinical trials in humans, with the results
expected in late 2011.
Conclusions
The conservation of miR-122 between
vertebrates and its high expression level
in the liver suggest that it is likely to
have important biological functions. The
identification of miR-122 targets has
allowed some of these roles to be deter-
mined, in particular its association with
cholesterol metabolism. The relief of miR-
122-mediated inhibition of CAT-1 by
HuR, and the role for miR-122 in HCV
replication, suggest that miRNA activity
extends beyond straightforward repression
and may take many different forms.
Important unanswered questions include
the reasons behind the very high expression
of miR-122: the tumor suppressive activity
ofmiR-122 inHCC suggests itisimportant
in maintaining a healthy liver, but it is
intriguing that it can be effectively depleted
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over the course of several weeks without
any occurrence of liver toxicity.
41 The
circadian regulation of miR-122 precursors
and targets despite unaltered mature miR-
122 levels suggests that miRNA function
may not be determined simply by expres-
sion level. The role of miR-122 in HCV
replication is providing an exciting avenue
for developmentofa novelantiviraltherapy;
it will be very interesting to find out
whether it is effective in human patients.
Finally, the mechanism of this regulation is
an important question that has not yet been
fully answered.
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